The program is intended to produce therapeutic molecules for the treatment of inflammatory airway diseases including rhinitis, asthma and chronic obstructive pulmonary disease (COPD). The trial data showed
Morphotek, a subsidiary of Eisai Corporation of North America, has reported that the FDA has agreed to and approved the design of a single, pivotal, Phase III clinical
China Biologic Products, a plasma-based pharmaceutical company, has reported that its indirect majority owned subsidiary, Shandong Taibang Biological Products, has completed the government approval process for the transfer
Calixa Therapeutics, a biopharmaceutical company, has reported positive results from a Phase I trial of intravenous CXA-101, a novel cephalosporin antibiotic with excellent in vitro anti-pseudomonal activity. According
The approval was based on results of two randomized, double-blind, active-controlled, multinational studies (studies 308 and 313) that evaluated Tygacil for the treatment of community-acquired bacterial pneumonia (CABP)
ThermoDox is currently being evaluated under a special protocol assessment with the FDA in a 600 patient, global Phase III trial in patients with non-resectable primary liver cancer.
B Braun’s distribution territory will be world-wide, excluding the US, Canada, Mexico, Japan, the Middle East, Australia, New Zealand, Greece, South Africa and China. The definitive agreement is
The main products in Stallergenes’s injectable and sublingual ranges will soon be the subject of registration applications. This partnership reportedly enables Stallergenes to meet more than 80% of
Under the terms of the agreement, the kits will be sold under both companies’ names. Kits will be shipped directly from Stemgent, and representatives from both Stemgent and
According to Quick-Med, the Nimbus is a next-generation wound care technology that is non-toxic, long-lasting and not blocked by organics such as blood, urine and perspiration. Ladd Greeno,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.